Endothelial Dysfunction Using Flow-Mediated Dilatation Among Individuals with Pre-Impaired Glucose Tolerance (Pre-IGT)
DOI:
https://doi.org/10.15605/jafes.039.02.19Keywords:
Endothelial dysfunction (ED), Insulin resistance (IR), Pre-impaired Glucose Tolerance (Pre-IGT), Hyperinsulinemia, Type 2 Diabetes Mellitus (DM), Cardiovascular Disease (CVD) RisksAbstract
Objectives. Pre-impaired glucose tolerance (pre-IGT) is a prediabetes stage characterized by normoglycemia and compensatory hyperinsulinemia due to insulin resistance. Hyperinsulinemia increases cardiovascular disease (CVD) risk, especially, endothelial dysfunction (ED). However, there is paucity of studies on ED with hyperinsulinemia alone, particularly in individuals with pre-IGT. This study aimed to determine the presence of ED using brachial artery flow-mediated dilatation (FMD) among adult participants with pre-IGT and its correlation with insulin levels and other related clinical parameters.
Methodology. This is a cross-sectional analytical study. We screened adult patients with risk factors for developing diabetes (first-degree relative with type 2 diabetes mellitus, obesity, history of gestational diabetes and polycystic ovary syndrome). Brachial artery FMD was performed among participants with pre-IGT and findings were correlated with CVD risk factors using Pearson’s correlation and linear regression.
Results. Of the 23 pre-IGT patients, 5 (21.74%) had decreased FMD values with significant associations with serum insulin and HbA1c. It was further observed that for every 1-unit increase in second-hour serum insulin and in HbA1c, there was a decrease in FMD values by 0.38% and 0.50%, respectively. Serum insulin was elevated, while other biochemical parameters were normal. Moreover, participants with low FMD were older, with higher BMI and had higher HBA1c, total cholesterol and low-density lipoprotein (LDL) cholesterol.
Conclusion. As early as the pre-IGT stage, endothelial dysfunction using the FMD test is already present, with red flags on other CVD risk factors already developing.
etes stage characterized by normoglycemia and compensatory hyperinsulinemia due to insulin resistance. Hyperinsulinemia increases cardiovascular disease (CVD) risk, especially, endothelial dysfunction (ED). However, there is paucity of studies on ED with hyperinsulinemia alone, particularly in individuals with pre-IGT. This study aimed to determine the presence of ED using brachial artery flow-mediated dilatation (FMD) among adult participants with pre-IGT and its correlation with insulin levels and other related clinical parameters.
Methods: This is a cross-sectional analytical study. We screened adult patients with risk factors for developing diabetes (First-degree relative with type 2 diabetes mellitus, obesity, history of gestational diabetes, and polycystic ovary syndrome). Brachial artery FMD was performed among participants with pre-IGT, and findings were correlated with CVD risk factors using Pearson’s correlation and linear regression.
Results: Of the 23 pre-IGT patients, five (21.74%) had decreased FMD values with significant associations with serum insulin and HbA1c, wherein every 1-unit increase in second-hour serum insulin and in HbA1c decrease FMD values by 0.38% and 0.50%, respectively. Serum insulin was elevated, while other biochemical parameters were normal. Moreover, participants with low FMD were older, more obese, and have higher HBA1c, total cholesterol, and LDL.
Conclusion: As early as the pre-IGT stage, endothelial dysfunction using FMD test is already present, with red flags on other CVD risk factors already developing.
Downloads
References
1. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi E. Natural history of -cell adaptation and failure in type 2 diabetes. Mol Aspects Med. 2015;42:19-41. https://pubmed.ncbi.nlm.nih.gov/25542976 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404183 https://doi.org/10.1016/j.mam.2014.12.002
2. Kraft JR. Detection of diabetes mellitus in situ (occult diabetes). Lab Med. 1975;6(2):10-22. https://doi.org/10.1093/labmed/6.2.10
3. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37(6):667-87. https://pubmed.ncbi.nlm.nih.gov/3289989 https://doi.org/10.2337/diab.37.6.667
4. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493-500. https://pubmed.ncbi.nlm.nih.gov/15483086. https://doi.org/10.1210/jc.2004-1133
5. Hupfeld CJ, Courtney CH Olefsky JM. Type 2 diabetes mellitus: etiology, pathogenesis and natural history. In: Jameson JL, De Groot LJ, eds. Endocrinology adult and paediatric, vol. 1, 6th ed. Philadelphia: Saunders Elsevier. 2010.
6. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res. 2005;97(7):725-33. https://pubmed.ncbi.nlm.nih.gov/16123336 https://doi.org/10.1161/01.RES.0000183730.52908.C6
7. Walcher D, Marx N. C-peptide in the vessel wall. Rev Diabet Stud. 2009;6(3):180-6. https://pubmed.ncbi.nlm.nih.gov/20039007 https://doi.org/10.1900/RDS.2009.6.180
8. Vasic, Walcher D. C-peptide: A new mediator of atherosclerosis in diabetes. Mediators Inflamm. 2012;2012:858692. https://pubmed.ncbi.nlm.nih.gov/22547909 https://doi.org/10.1155/2012/858692
9. Chen Z, He J, Ma Q, Xiao M. Association between c-peptide level and subclinical myocardial injury. Front Endocrinol (Lausanne). 2021;12:680501. https://pubmed.ncbi.nlm.nih.gov/34456859 https://doi.org/10.3389/fendo.2021/680501
10. Baltali M, Korkmaz ME, Kiziltan HT, Muderris IH, Ozin B, Anarat R. Association between postprandial hyperinsulinemia and coronary artery disease among non-diabetic women: A case control study. Int J Cardiol. 2003;88(2-3):215-21. https://pubmed.ncbi.nlm.nih.gov/12714201 https://doi.org/10.1016/s0167-5273(02)00399-6
11. Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes and impaired tolerance: A systematic review. Diabet Med. 2006;23(6):609-16. https://pubmed.ncbi.nlm.nih.gov/16759301 https://doi.org/10.1111/j.1464-5491.2005.01725.x
12. Su Y, Liu XM, Sun YM, Wang YY, Luan Y, Wu Y. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance and type 2 diabetes mellitus. Am J Cardiol. 2008;102(4):497-8. https://pubmed.ncbi.nlm.nih.gov/18678313 https://doi.org/10.1016/j.amjcard.2008.03.087
13. Li CH, Wu JS, Yang YC, Shih CC, Lu FH, Chang CJ. Increased arterial stiffness in subjects with impaired glucose tolerance and newly diagnosed diabetes but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2012;97(4):E658-662. https://pubmed.ncbi.nlm.nih.gov/22337914 https://doi.org/10.1210/jc.2011-2595
14. Yamaji T, Harada T, Hashimoto Y, et al. Pre-impaired fasting glucose state is a risk factor for endothelial dysfunction: Flow-mediated dilation Japan (FMD-J) study. BMJ Open Diabetes Res Care. 2020;8(1):e001610. https://pubmed.ncbi.nlm.nih.gov/33028539 https://doi.org/10.1136/bmjdrcc-2020-001610
15. Matawaran B, Mercado-Asis LB. Comparison of pancreatic insulin response to hyperglycemia among Filipino subjects of various glycemic status. Philipp J Intern Med. 2009;47(1):25-30.
16. Valdez VAU, Mercado-Asis LB, Lopez AA, et al. Determination of nonalcoholic fatty liver disease in patients with pre-impaired glucose tolerance. Philipp J Intern Med. 2017;55(2):1-6.
17. Torres-Salvador PD, Malaza G, Mercado-Asis LB. Correlation of glycosylated hemoglobin and oral glucose tolerance test results in hyperinsulinemic pre-impaired glucose tolerance state versus normoinsulinemic-normal OGTT. J Med UST. 2018;2(1):155-9. https://doi.org/10.35460/2546-1621.2017-0042
18. Cefalu WT, Buse JB, Tuomilehto J, et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from Diabetes Care Editors’ Expert Forum. Diabetes Care. 2016;39(7):1186-1201. https://pubmed.ncbi.nlm.nih.gov/27631469 https://doi.org/10.2337/dc16-0873
19. World Health Organization (WHO). International Association for the Study of Obesity (IASO) and International Obesity Task Force (IOTF). The Asia-Pacific perspective: redefining obesity and its treatment. 2000. https://iris.who.int/bitstream/handle/10665/206936/0957708211_eng.pdf. Accessed on March 4, 2022.
20. Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence. A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38(9):1777-1803. https://pubmed.ncbi.nlm.nih.gov/26246459 https://doi.org/10.2337/dci15-0012
21. Viechtbauer W, Smits L, Kotz D, et al. A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol. 2015;68(11): 1375-9. https://pubmed.ncbi.nlm.nih.gov/26146089 https://doi.org/10.1016/j.jclinepi.2015.04.014
22. Skaug EA, Madssen E, Aspenes ST, Wisløff U, Ellingsen Ø. Cardiovascular risk factors have larger impact on endothelial function in self-reported health women than men in the HUNT3 Fitness study. PLoS One. 2014;.9(7):e101371. https://pubmed.ncbi.nlm.nih.gov/24991924 https://doi.org/10.1371/journal.pone.0101371
23. Crofts C, Schofield G, Zinn C, Wheldon M, Kraft J. Identifying hyperinsulinemia in the absence of impaired glucose tolerance: An examination of the Kraft database. Diabetes Res Clin Pract. 2016;118:50-57. https://pubmed.ncbi.nlm.nih.gov/27344544 https://doi.org/10.1016/j.diabres.2016.06.007
24. Crofts CAP, Schofield G, Wheldon MC, Zinn C, Kraft JR. Determining a diagnostic algorithm for hyperinsulinemia. J Insul Resist. 2019;4(1): a49. https://doi.org/10.4102/jir.v4i1.49
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. https://pubmed.ncbi.nlm.nih.gov/11368702 https://doi.org/10.1001/jama.285.19.2486
26. Calderón-Gerstein WS, López-Peña A, Macha-Ramírez R,et al. Endothelial dysfunction assessment by flow-mediated dilation in a high-altitude population. Vasc Health Risk Manag. 2017;13:421-6. https://pubmed.ncbi.nlm.nih.gov/29200863 https://doi.org/10.2147/VHRM.S151886
27. Kuvin JT, Patel AR, Sliney KA, et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol. 2001;38(7):1843-9. https://pubmed.ncbi.nlm.nih.gov/11738283 https://doi.org/10.1016/s0735-1097(01)01657-6
28. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23(3):295-301. https://pubmed.ncbi.nlm.nih.gov/10868854 https://doi.org/10.2337/diacare.23.3.295
29. Sciacqua A, Maio R, Miceli S, et al. Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One. 2012;7(9):e44470. https://pubmed.ncbi.nlm.nih.gov/23028545 https://doi.org/10.1371/journal.pone.0044470
30. Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995;5(6):464-72. https://pubmed.ncbi.nlm.nih.gov/8680609 https://doi.org/10.1016/1047-2797(95)00062-3
31. Fonseca VA. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone. 2007;8 Suppl 7:S7-18. https://pubmed.ncbi.nlm.nih.gov/18159645 https://doi.org/10.1016/s1098-3597(07)80017-2
32. Thomas DD, Corkey BE, Istfan N, Apovian CM. Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc. 2019;3(9):1727-47. https://pubmed.ncbi.nlm.nih.gov/31528832 https://doi.org/10.1210/js.2019-00065
33. Cabrera de León A, Oliva García JG, Marcelino Rodríguez I, et al. C-peptide as a risk factor of coronary artery disease in the general population. Diab Vasc Dis. Res 2015;12(3):199-207. https://pubmed.ncbi.nlm.nih.gov/25696117 https://doi.org/10.1177/1479164114564900
34. Layton J, Li X, Shen C, et al. Type 2 diabetes genetic risk scores are associated with increased type 2 diabetes risk among African Americans by cardiometabolic status. Clin Med Insights Endocrinol Diabetes. 2018;11:1179551417748942. https://pubmed.ncbi.nlm.nih.gov/29326538 https://doi.org/10.1177/1179551417748942l
35. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7):1149-60. https://pubmed.ncbi.nlm.nih.gov/14522472 https://doi.org/10.1016/s0735-1097(03)00994-x
36. Quyyomi AA. Prognostic value of endothelial function. Am J Cardiol. 2003;91(12A):19-24H. https://pubmed.ncbi.nlm.nih.gov/12818731 https://doi.org/10.1016/s0002-9149(03)00430-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jeannine Ann Salmon, Ann Lorraine Magbuhat, Ruby Jane Guerrero-Sali, Francis Purino, John Rey Macindo, Leilani Mercado-Asis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
